Malte Peters - 08 Jan 2026 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Role
President & CEO, Director
Signature
/s/ Julie Fogarty, as attorney-in-fact
Issuer symbol
TNGX
Transactions as of
08 Jan 2026
Net transactions value
$0
Form type
4
Filing time
12 Jan 2026, 06:15:20 UTC
Previous filing
04 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Peters Malte President & CEO, Director C/O TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON /s/ Julie Fogarty, as attorney-in-fact 12 Jan 2026 0001876563

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNGX Common Stock Award $0 +350,000 +2000% $0.000000 367,500 08 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNGX Stock Option (Right to Buy) Award $0 +1,650,000 $0.000000 1,650,000 08 Jan 2026 Common Stock 1,650,000 $11.06 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2 This option shall vest and become exercisable over a four-year period, with 25% vesting on January 8, 2027 and the remaining option shares vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.